Financials Anebulo Pharmaceuticals, Inc.
Equities
ANEB
US0345691036
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | -1.65% | -1.42% | -14.05% |
Valuation
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 159.2 | 121.4 | 60.24 | 53.94 | - | - |
Enterprise Value (EV) 1 | 159.2 | 121.4 | 60.24 | 53.94 | 53.94 | 53.94 |
P/E ratio | -2.41 x | -17.9 x | -5 x | -4.69 x | -3.78 x | -3.06 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | -22,314,660 x | - | - | - | - |
FCF Yield | - | -0% | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 23,345 | 23,345 | 25,633 | 25,933 | - | - |
Reference price 2 | 6.820 | 5.200 | 2.350 | 2.080 | 2.080 | 2.080 |
Announcement Date | 9/22/21 | 9/9/22 | 9/20/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -3.614 | -6.831 | -11.78 | -11.93 | -18.01 | -24.52 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -30.25 | -6.826 | -11.73 | -11.77 | -17.88 | -24.36 |
Net income 1 | -38.46 | -6.826 | -11.73 | -11.77 | -17.88 | -24.36 |
Net margin | - | - | - | - | - | - |
EPS 2 | -2.830 | -0.2900 | -0.4700 | -0.4433 | -0.5500 | -0.6800 |
Free Cash Flow | - | -5.44 | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 9/22/21 | 9/9/22 | 9/20/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -1.071 | -1.88 | -2.325 | -2.612 | -3.813 | -2.864 | -2.494 | -2.544 | -2.76 | -1.664 | -3.589 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.073 | -1.876 | -2.323 | -2.612 | -3.827 | -2.798 | -2.496 | -2.481 | -2.717 | -1.654 | -3.563 |
Net income 1 | -1.073 | -1.876 | -2.323 | -2.612 | -3.827 | -2.798 | -2.496 | -2.481 | -2.717 | -1.654 | -3.563 |
Net margin | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.0500 | -0.0800 | -0.1000 | -0.1100 | -0.1500 | -0.1100 | -0.1000 | -0.1000 | -0.1100 | -0.0600 | -0.1233 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/11/22 | 5/11/22 | 9/9/22 | 11/10/22 | 2/10/23 | 5/11/23 | 9/20/23 | 11/14/23 | 2/13/24 | 5/15/24 | - |
Balance Sheet Analysis
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | -5.44 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share 2 | -0.3600 | -0.2300 | -0.3900 | -0.3800 | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 9/22/21 | 9/9/22 | 9/20/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.05% | 53.94M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.57% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- ANEB Stock
- Financials Anebulo Pharmaceuticals, Inc.